Imiquimod a new adjuvant for telomerase peptide vaccine: A phase I trial in patients with inoperable pancreatic cancer.

被引：0
|
作者：
Bernhardt, SL
Buanes, TA
Moller, M
Eriksen, JA
Geudernack, G
机构：
[1] Univ Oslo, Ullevaal Hosp, N-0407 Oslo, Norway
[2] Gemvax, Porsgrunn, Norway
[3] Norwegian Radium Hosp, Oslo, Norway
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：867S / 867S
页数：1
相关论文
共 50 条
  • [1] Gemcitabine (G) combined with gefitinib in patients with inoperable or metastatic pancreatic cancer. A phase II trial
    Fountzilas, G.
    Murray, S.
    Xiros, N.
    Karayannopoulou, G.
    Dafni, U.
    Linardou, H.
    Kalogera-Fountzila, A.
    Bobos, M.
    Koumarianou, A.
    Kosmidis, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] TELOMERASE-PEPTIDE VACCINE TOGETHER WITH GEMCITABINE IN ADVANCED PANCREATIC CANCER PATIENTS
    Staff, C. E. B.
    Mozaffari, F. M.
    Liljefors, M.
    Mosolits, S.
    Frodin, J.
    Choudhury, A.
    Mellstedt, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 26 - 26
  • [3] A phase I study of a mutant KRAS-targeted long peptide vaccine in patients at high risk of developing pancreatic cancer.
    Haldar, Saurav Daniel
    Judkins, Carol
    Ferguson, Anna
    Abou Diwan, Elizabeth
    Lim, Su Jin
    Wang, Hao
    Nauroth, Julie
    Goggins, Michael
    Laheru, Dan
    Jaffee, Elizabeth M.
    Azad, Nilofer Saba
    Zaidi, Neeha
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS758 - TPS758
  • [4] Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients
    Miyazawa, Motoki
    Katsuda, Masahiro
    Maguchi, Hiroyuki
    Katanuma, Akio
    Ishii, Hiroshi
    Ozaka, Masato
    Yamao, Kenji
    Imaoka, Hiroshi
    Kawai, Manabu
    Hirono, Seiko
    Okada, Ken-ichi
    Yamaue, Hiroki
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (04) : 973 - 982
  • [5] Immunotherapeutic role of mutant ras peptide-based vaccine as an adjuvant in pancreatic and colorectal cancer.
    Toubaji, A
    Achtar, MS
    Herrin, VE
    Provenzano, M
    Bernstein, S
    Brent-Steel, T
    Marincola, F
    Khleif, SN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 184S - 184S
  • [6] A phase I/II study of telomerase peptide vaccination of patients with non-small cell lung cancer.
    Brunsvig, PF
    Gjertsen, MK
    Kvalheim, G
    Aamdal, S
    Markowski-Grimsrud, CJ
    Sve, I
    Dyrhaug, M
    Trachsel, S
    Moller, M
    Eriksen, J
    Gaudernack, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 185S - 185S
  • [7] Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial
    Aamdal, E.
    Gaudernack, G.
    Inderberg, E. M.
    Rasch, W.
    Bjorheim, J.
    Aamdal, S.
    Guren, T. K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [8] Phase II clinical trial using novel peptide vaccine cocktail as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
    Yamaue, Hiroki
    Miyazawa, Motoki
    Katsuda, Masahiro
    Maguchi, Hiroyuki
    Ishii, Hiroshi
    Yamao, Kenji
    Kawai, Manabu
    Hirono, Seiko
    Okada, Ken-Ichi
    Shimizu, Atsushi
    Kitahata, Yuji
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] A phase I trial of erlotinib, gemcitabine and radiation for patients with locally advanced, unresectable pancreatic cancer.
    Kortmansky, JS
    O'Reilly, EM
    Minsky, BD
    Puleio, SA
    Winkelmann, J
    Kelsen, DP
    Schwartz, GK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 334S - 334S
  • [10] A Phase I/II trial of weekly gemcitabine with celecoxib and thalidomide for patients with advanced pancreatic cancer.
    Densmore, JJ
    Fox, JR
    Kannarkat, G
    Morgan, JK
    Petroni, G
    Blount, T
    Sullivan, K
    Williams, ME
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 367S - 367S
12345